Castle biosciences stock.

Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.

Castle biosciences stock. Things To Know About Castle biosciences stock.

3 Haz 2023 ... The company's shares closed yesterday at $22.73. Souda covers the Healthcare sector, focusing on stocks such as Guardant Health, Repligen, and ...Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher test in patients with Barrett's esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) …Jul 7, 2023 · In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00. Below is ... How much is Castle Biosciences stock worth today? ( NASDAQ: CSTL) Castle Biosciences currently has 26,910,548 outstanding shares. With Castle Biosciences stock trading at $18.06 per share, the total value of Castle Biosciences stock (market capitalization) is $486.00M. Castle Biosciences stock was originally listed at a price of …

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.

Best Stock Of The Week Castle Biosciences Cstl Option Informants Based on 3 Wall Street analysts offering 12 month price targets for Castle Biosciences in the last 3 months. . 1 day agoSVB Securities analyst Puneet Souda maintained a Buy rating on Castle Biosciences CSTL - Research Report on November 2 and set a price target of …Nov 22, 2023 · November 22, 2023 at 3:28 AM · 2 min read. Last week, Castle Biosciences, Inc. ( NASDAQ:CSTL) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares ...

The shares are expected to begin trading on The Nasdaq Global Market on July 25, 2019 under the symbol “CSTL.” All of the common stock in the offering is being ...52.55K (21.02% of Avg) 65 Day Avg: 250.03K Becton Dickinson & Co. Siemens Healthineers AG Qiagen N.V. Company & People Research & Ratings President, Chief Executive Officer & Director Franklin...Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences Third Quarter 2023 Conference Call. As a reminder, today’s call is being recorded.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $34.00 average price target, implying a 67.49% upside from current levels.

31 Eki 2023 ... About Castle Biosciences Inc (CSTL). Before we jump into Castle Biosciences Inc's stock price, history, target price and what caused it to ...

Castle Biosciences, Inc. Common Stock (CSTL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Jun 5, 2023 · Shares of Castle Biosciences ( CSTL 2.42%) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is down ... 7 Nis 2021 ... Product details ... Do you want to earn up to a 1117163% annual return on your money by two trades per day on Castle Biosciences Inc CSTL Stock?According to 7 analyst offering 12-month price targets in the last 3 months, Castle Biosciences has an average price target of $35.14 with a high of $41.00 and a low of $25.00.Secrets and treasures of the ancient world are scattered all across the globe. One of the most incredible discoveries in the history of exploring the ancient world was recently unearthed completely by accident.Jun 5, 2023 · Castle Biosciences (CSTL) In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences, with a price target of $38.00 . The company’s shares closed last ... Castle Biosciences, Inc. Common Stock (CSTL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 39.75% so far this month. During the month of June, Castle Biosciences Inc’s stock price has reached a high of $24.55 and a low of $9.26. Over the last year, Castle Biosciences Inc has hit prices as high as $36.10 and as low as $9.26. Year to date ...

Contact Information. Customer Service: 866-788-9007 Option 1 [email protected]. Reimbursement: 866-788-9007 Option 3 [email protected] Biosciences stock quote and CSTL charts. Latest stock price today and the US's most active stock market forums.3 Haz 2023 ... The company's shares closed yesterday at $22.73. Souda covers the Healthcare sector, focusing on stocks such as Guardant Health, Repligen, and ...Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47.Castle Biosciences Inc. Watch list Set a price target alert After Hours Last Updated: Nov 3, 2023 5:21 p.m. EDT Delayed quote $ 17.95 -0.03 -0.17% After Hours Volume: 7.02K Advanced Charting... Castle Creek Biosciences: Cell and Gene Therapy Company : Castle Creek Biosciences, Inc. “ We are building a leading cell and gene therapy company for patients and families seeking relief from devastating genetic diseases. ”. Matthew Gantz, President and Chief Executive Officer. Courtesy of debra—The Dystrophic Epidermolysis Bullosa ...

The estimated Net Worth of David S Kabakoff is at least $76.2 Million dollars as of 17 June 2021. David Kabakoff owns over 30,000 units of Castle Biosciences stock worth over $11,536,949 and over the last 4 years he sold CSTL stock worth over $64,362,650. In addition, he makes $288,339 as Independent Director at Castle …

Castle Biosciences’ technology approach objectively measures optimal combinations of epithelial, immune, and stromal processes in the context of tissue morphology to extract tissue profiles (information from digital whole side images of tissue biopsies) that are correlated with diagnosis and prognosis. Our tissue systems biology approach integrates …Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher test in patients with Barrett's esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver ...See the latest Castle Biosciences Inc stock price (CSTL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Shares of Castle Biosciences ( CSTL 2.42%) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is down ...Which technical analysis tools can be used to analyze Castle Biosciences, Inc.? Check out various oscillators, moving averages and other technical ...Dec 1, 2023 · Stock Info Stock Quote Price $19.88 Volume 52,546 Change +0.03 % Change +0.15% Today's Open $19.69 Previous Close $19.85 Intraday High $20.26 Intraday Low $19.69 52-Week High $29.59 52-Week Low $9.26 Pricing delayed by 20 minutes. Last Updated 11/24/2023 1:00 PM ET Stock Chart View stock chart as data table From: To: Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.Mr. Spiess CSTL stock SEC Form 4 insiders trading. Bernhard has made over 9 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of CSTL stock worth $29,820 on 10 December 2021.. The largest trade he's ever made was selling 40,000 units of Castle …Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.By providing your email address below, you are providing consent to Castle Biosciences to send you the requested Investor Email Alert updates. * Required. Email Address*. Investor Alert Options*. News. Events & Presentations. Quarterly Reports. Annual Reports. SEC Filings.

Castle Biosciences (CSTL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 2. Analyst Catherine Ramsey Schulte from Robert W. Baird remains ...

Simply Wall St. June 8, 2023 at 3:34 AM · 3 min read. The Castle Biosciences, Inc. ( NASDAQ:CSTL) share price has fared very poorly over the last month, falling by a substantial 34%. Instead of ...

All earnings call transcripts on Castle Biosciences, Inc. (CSTL) stock. Read or listen to the conference call. Download the investor presentation - earnings ...Biosciences; Research Funding - Castle Biosciences. CPG: Other Remuneration - Indiana University. DM: President and CEO - Castle Biosciences; Stock Ownership - Castle Biosciences. KMO: Director of ...Europe PMC is an archive of life sciences journal literature.Apr 4, 2022 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ... Dec 1, 2023 · View Castle Biosciences, Inc CSTL investment & stock information. Get the latest Castle Biosciences, Inc CSTL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Jun 5, 2023 · According to 7 analyst offering 12-month price targets in the last 3 months, Castle Biosciences has an average price target of $35.14 with a high of $41.00 and a low of $25.00. Castle Biosciences is forecast to grow earnings and revenue by 32.8% and 14.8% per annum respectively. EPS is expected to grow by 32.1% per annum. Return on equity is forecast to be -26.8% in 3 years.On November 3, 2023, Castle Biosciences Inc (CSTL) stock is expected to experience positive growth, according to analysts. The 8 analysts offering 12-month price forecasts for CSTL have a median target of $32.50, with a high estimate of $40.00 and a low estimate of $25.00.Get the latest Castle Biosciences, Inc. (CSTL) stock news and headlines to help you in your trading and investing decisions.Jean Carruthers Faculty Owner/Co-Owner Founder/Co-Founder: Carruthers Instruments; Consulting Fee: Alastin Skincare, Allergan Aesthetics, Appiell, Avari, Evolus ...In a report released on July 7, Puneet Souda from SVB Securities maintained a Buy rating on Castle Biosciences (CSTL – Research Report).The company’s shares closed last Friday at $20.30 ...Castle Biosciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CSTL updated stock price target summary.

Castle Biosciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall …Castle will pay an initial $65 million, including $32.5 million in cash, debt, transaction expenses and working capital, as well as $32.5 million in Castle common stock.Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a paper in Clinical, Cosmetic and Investigational Dermatology highlighting a clinician-derived, real-world algorithm that provides a framework to incorporate DecisionDx®-SCC test results …Instagram:https://instagram. tower semiconductor ltdvanguard fixed incomeb2 goldbest real estate stocks to buy Jun 5, 2023 · According to 7 analyst offering 12-month price targets in the last 3 months, Castle Biosciences has an average price target of $35.14 with a high of $41.00 and a low of $25.00. Contact Information. Customer Service: 866-788-9007 Option 1 [email protected]. Reimbursement: 866-788-9007 Option 3 [email protected] altair engineering incweed stock news In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.Castle Biosciences stock gains ~9% after co reports beat-and-raise Q2 SA News Tue, Aug. 09, 2022 1 Comment. Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $34.8M beats by $6.43M flexible spending account providers The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical …2 Ağu 2023 ... Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health ... stock-based compensation expense, change in fair value of contingent ...